Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences, Gastroenterology, vol.126, issue.6, pp.1504-1521, 2004. ,
DOI : 10.1053/j.gastro.2004.01.063
Epidemiology and Natural History of Inflammatory Bowel Diseases, Gastroenterology, vol.140, issue.6, pp.1785-1794, 2011. ,
DOI : 10.1053/j.gastro.2011.01.055
URL : https://hal.archives-ouvertes.fr/hal-00631553
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review, Gastroenterology, vol.142, issue.1, pp.46-54, 2012. ,
DOI : 10.1053/j.gastro.2011.10.001
Inflammatory bowel disease, Inflammatory Bowel Diseases, vol.14, issue.Supplement, pp.9-11, 2008. ,
DOI : 10.1097/00054725-200810001-00005
IBD: a family affair Role of genetic and environmental factors in British twins with inflammatory bowel disease Concordance of inflammatory bowel disease among Danish twins: results of a nationwide study, 525?39. 10, pp.1075-1081, 2000. ,
The relationship between inflammatory bowel disease and socioeconomic variables, The American Journal of Gastroenterology, vol.119, issue.7, pp.2117-2125, 2001. ,
DOI : 10.1016/0021-9681(71)90087-7
Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease Appendectomy and protection against ulcerative colitis, 1588?94. 16. Andersson RE, pp.808-814, 2001. ,
Appendectomy is followed by increased risk of Crohn's disease Smoking and inflammatory bowel disease: a meta-analysis, 40?6. 18. Mahid SS, pp.1462-1471, 2003. ,
A meta-analysis of the role of smoking in inflammatory bowel disease, Digestive Diseases and Sciences, vol.284, issue.12 ,
DOI : 10.1007/BF01536701
Psychological stress in IBD: new insights into pathogenic and therapeutic implications, 1481?91. 21. Guide affection de longue durée Maladie de Crohn. HAS, 2005. ,
DOI : 10.1136/gut.2005.064261
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774724
The Clustering of Other Chronic Inflammatory Diseases in Inflammatory Bowel Disease: A Population-Based Study, Gastroenterology, vol.129, issue.3, 2005. ,
DOI : 10.1053/j.gastro.2005.06.021
The natural history of adult ,
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease Risk of early surgery for Crohn's disease: implications for early treatment strategies, Gut. Am J Gastroenterol, vol.4998, issue.612, pp.2712-2720, 2001. ,
Meta-analysis: mortality in Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.21, issue.7 ,
DOI : 10.1111/j.1365-2036.2006.03132.x
Guidelines for the management of inflammatory bowel disease in adults, 571?607. 31. Guide affection de longue durée Rectocolite hémorragique évolutive. HAS, 2008. ,
DOI : 10.1136/gut.2010.224154
Faecal incontinence in inflammatory bowel disease: associations and effect on quality of life Changes in extent of ulcerative colitis: a study on the course and prognostic factors, J Crohns Colitis. Scand J Gastroenterol, vol.731, issue.83, pp.302-313, 1996. ,
Ulcerative colitis and clinical course: Results of a 5-year population-based follow-up study (the IBSEN study), Inflammatory Bowel Diseases, vol.12, issue.7, pp.543-50, 2006. ,
DOI : 10.1097/01.MIB.0000225339.91484.fc
Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey, 1044?52. 37. Siebert, 2007. ,
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee, Gut. Am J Gastroenterol, vol.55105, issue.524, pp.501-523, 2006. ,
Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients Immune sensitization to yeast antigens in ASCA-positive patients with Crohn's disease, 432?41. 41. Konrad A, pp.97-105, 2004. ,
Ulcerative Colitis, New England Journal of Medicine, vol.365, issue.18, pp.1713-1738, 2011. ,
DOI : 10.1056/NEJMra1102942
URL : https://hal.archives-ouvertes.fr/hal-01303796
Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies, 639?45. 44. D'Haens GR, 2012. ,
DOI : 10.1016/j.cgh.2012.01.010
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease, Inflamm Bowel Dis, vol.15, issue.45, 2009. ,
Predictors of Crohn's disease Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients, Gastroenterology. Dig Dis Sci, vol.13038, issue.476, pp.1137-1183, 1993. ,
Crohn's disease: an intervention study European evidence based consensus on the diagnosis and management of Crohn's disease: current management, 1093?9. 49, pp.16-35, 2001. ,
Diet therapy for inflammatory bowel diseases: the established and the new Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies Review article: appropriate use of corticosteroids in Crohn's disease The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study, World J Gastroenterol. Clin Gastroenterol Hepatol. Am J Gastroenterol. Aliment Pharmacol Ther. Gastroenterology, vol.22210026121, issue.515632, pp.1345-53, 2001. ,
Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone ,
Serious infection and mortality in patients with Crohn's disease: more than 5 years of followup in the TREAT registry Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery, 1409?22. 57. Cosnes J, Nion-Larmurier I, 2012. ,
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study Increased risk for non-melanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease, Lancet. Gastroenterology, vol.374141, issue.605, pp.1621-1628, 2009. ,
Cyclosporine in severe ulcerative colitis refractory to steroid therapy Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity, N Engl J Med. Nature, vol.330256, issue.63, pp.1841-1846, 1975. ,
DOI : 10.1056/nejm199406303302601
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis):392?400.e3. 66. Van Den Infliximab induced T lymphocyte apoptosis in Crohn's disease, Gastroenterology. J Rheumatol, vol.14674, issue.67, 2005. ,
Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor, Nature Clinical Practice Rheumatology, vol.52, issue.8, pp.602-612, 2006. ,
DOI : 10.1034/j.1399-3062.2003.00005.x
Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease, 929?36. 74. Reddy JG, Loftus EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases, pp.837-55, 2006. ,
DOI : 10.1053/j.gastro.2008.01.012
CLASSIC-I Study the Efficacy of Adalimumab, Gastroenterology, vol.130, issue.6 ,
DOI : 10.1053/j.gastro.2006.03.050
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial, 52?65. 78. Sandborn WJ, 2007. ,
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.239-250, 2007. ,
DOI : 10.1056/NEJMoa062897
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies):92?101. 81. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn?s disease: a critical systematic review Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease, ):1264?75. 82. Karmiris K, pp.1628-1668, 2009. ,
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort, Gut, vol.58, issue.4, pp.492-500, 2009. ,
DOI : 10.1136/gut.2008.155812
Monitoring functional serum antitumor necrosis factor antibody level in Crohn?s disease patients who maintained and those who lost response to anti-TNF Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease, Inflamm Bowel Dis. Gastroenterology. Clin Gastroenterol Hepatol, vol.161242, issue.8947, pp.542-553, 2003. ,
Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial, ):1861?8. 92. Colombel JF, 2008. ,
DOI : 10.1053/j.gastro.2008.03.004
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective, Annals of the Rheumatic Diseases, vol.72, issue.2, pp.165-78, 2013. ,
DOI : 10.1136/annrheumdis-2012-202545
Antibody response to infliximab and its impact on pharmacokinetics can be transient Antinuclear antibodies associate with loss of response to antitumour necrosis factor-? therapy in psoriasis: a retrospective, observational study, ):962?71. 95. Pink AE, pp.780-785, 2009. ,
Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.18, issue.7, pp.1199-206, 2012. ,
DOI : 10.1002/ibd.21839
The efficacy of shortening the dosing interval to once every six weeks in Crohn???s patients losing response to maintenance dose of infliximab, Alimentary Pharmacology & Therapeutics, vol.105, issue.3, pp.349-57, 2011. ,
DOI : 10.1111/j.1365-2036.2010.04523.x
The effect of dose escalation on trough levels in patients who lost response to infliximab ,
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial, Gut, vol.61, issue.2, pp.229-263, 2012. ,
DOI : 10.1136/gutjnl-2011-300755
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease, The American Journal of Gastroenterology, vol.26, issue.5, pp.1133-1139, 2010. ,
DOI : 10.1053/j.gastro.2006.11.041
Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab, Journal of Market Access & Health Policy, vol.74, issue.7, p.29229, 2015. ,
DOI : 10.1136/annrheumdis-2013-204101
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn???s Disease Patients Failing Infliximab, Digestive Diseases and Sciences, vol.132, issue.9, pp.2762-70, 2015. ,
DOI : 10.1053/j.gastro.2007.03.024
Stabilité de l'infliximab en solutions diluées, Congrès APHIF Paris, 2009. ,
Evaluation of the physicochemical and functional stability of diluted REMSIMA® upon extended storage ,
Maximizing the use of scarce resources: vial optimization, Rheumatology, vol.45, issue.3, pp.353-357, 2006. ,
DOI : 10.1093/rheumatology/kei234
Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy, Clin Exp Rheumatol, vol.26, issue.1, p.45, 2008. ,
THU0484-HPR???Role of ???vial sharing??? in achieving cost savings while using infliximab in rheumatology planned short stay unit, Annals of the Rheumatic Diseases, vol.71, issue.Suppl 3, pp.742-742, 2013. ,
DOI : 10.1136/annrheumdis-2012-eular.2449